Pulse Therapeutics, Inc.
Founder, President and CTO, Pulse Therapeutics, Inc.
Duke Creighton is the inventor of the technology employed by Pulse Therapeutics and has been involved in startup-to-post-IPO medical robotic companies for over twenty years. Duke possesses a deep expertise in cardiovascular and stroke therapies. His roles in the company include managing the pilot stroke study at multiple clinical sites in Australia, as well as successfully managing government, CRO, and HREC processes to ensure successful enrollment with a supporting data package. His responsibilities include developing and maintaining strong clinical relationships at thought-leading worldwide sites, including US, Europe, and Australasia. In addition to overseeing GMP, GLP, IEC 60601 compliance for the clinical trial, he managed the worldwide IP plan with fast-approval strategy for core system & method patents, resulting in multiple accelerated US approvals. Duke is also the author of successful SBIR grant proposals to the NIH and was the author of the 1st-Place business plan for the 2011 St. Louis Business Plan Competition. Prior to Pulse Therapeutics, Duke served as Senior Director of R&D at Stereotaxis, where over the course of fifteen years, he designed the current commercial robotic technology platform. He is responsible for at least 30 Stereotaxis patents. During his time at the company, he worked closely with the CEO, President, and Board of Directors to develop new technologies, techniques, and devices for precision EP catheter and IC/INR guide-wire navigation. Duke received his Ph. D. in Physics (emphasis in advanced medical robotics) from the University of Virginia in 1996. Francis also serves as a technology reviewer for the NIH, NCI, and NSF.